MA31086B1 - Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa. - Google Patents

Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa.

Info

Publication number
MA31086B1
MA31086B1 MA32076A MA32076A MA31086B1 MA 31086 B1 MA31086 B1 MA 31086B1 MA 32076 A MA32076 A MA 32076A MA 32076 A MA32076 A MA 32076A MA 31086 B1 MA31086 B1 MA 31086B1
Authority
MA
Morocco
Prior art keywords
methods
inhibitor
factor
dosage formulations
unitary dosage
Prior art date
Application number
MA32076A
Other languages
English (en)
Inventor
Uma Sinha
Stanley J Hollenbach
Keith Abe
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39110529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31086(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA31086B1 publication Critical patent/MA31086B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'INVENTION CONCERNE DES DOSES UNITAIRES DE COMPOSÉS INHIBITEURS DU FACTEUR XA ET DES PROCÉDÉS UTILISANT CES COMPOSÉS POUR INHIBER LA COAGULATION DU SANG CHEZ UN PATIENT HUMAIN. LA DOSE UNITAIRE DE COMPOSÉS INHIBITEURS DU FACTEUR XA DÉCRITE DANS LE PRÉSENT DOCUMENT NÉCESSAIRE POUR INHIBER LA COAGULATION CHEZ UN PRIMATE EST PLUS FAIBLE QUE LA DOSE UNITAIRE REQUISE POUR OBTENIR DES NIVEAUX SIMILAIRES D'INHIBITION DE LA COAGULATION CHEZ D'AUTRES MODÈLES D'ANIMAUX, TELS QUE LES RONGEURS. L'INVENTION CONCERNE ÉGALEMENT DES ESSAIS IN VITRO UTILES POUR PRÉDIRE L'ACTIVITÉ ANTI-THROMBOTIQUE IN VIVO CHEZ LES HUMAINS.
MA32076A 2006-12-08 2009-07-08 Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa. MA31086B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87379206P 2006-12-08 2006-12-08
US94762907P 2007-07-02 2007-07-02

Publications (1)

Publication Number Publication Date
MA31086B1 true MA31086B1 (fr) 2010-01-04

Family

ID=39110529

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32076A MA31086B1 (fr) 2006-12-08 2009-07-08 Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa.

Country Status (19)

Country Link
US (1) US8404724B2 (fr)
EP (1) EP2101760B1 (fr)
KR (1) KR101472765B1 (fr)
CN (1) CN105193799A (fr)
AU (1) AU2007333377B2 (fr)
CA (2) CA2671502C (fr)
CO (1) CO6220933A2 (fr)
CR (1) CR10914A (fr)
EC (1) ECSP099501A (fr)
ES (1) ES2409090T3 (fr)
HK (1) HK1134031A1 (fr)
IL (1) IL199219A (fr)
MA (1) MA31086B1 (fr)
NI (1) NI200900145A (fr)
NZ (1) NZ578180A (fr)
PT (1) PT2101760E (fr)
RU (2) RU2452484C2 (fr)
SG (1) SG10201504425SA (fr)
WO (1) WO2008073670A2 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
NZ552187A (en) 2004-06-18 2010-08-27 Millennium Pharm Inc Thiophene-2-carboxamide derivatives
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CN101094867B (zh) 2004-10-19 2011-08-24 隆萨股份公司 用于固相肽合成的方法
JP2009508835A (ja) 2005-09-16 2009-03-05 アロー セラピューティクス リミテッド ビフェニル誘導体及びｃ型肝炎の治療におけるその使用
US20090186810A1 (en) * 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
CA2651303A1 (fr) 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Inhibiteurs de facteur xa
WO2008057972A1 (fr) 2006-11-02 2008-05-15 Millennium Pharmaceuticals, Inc. Procédés de synthèse de sels pharmaceutiques d'un inhibiteur du facteur xa
US20080293704A1 (en) * 2007-01-05 2008-11-27 Millennium Pharmaceuticals, Inc. FACTOR Xa INHIBITORS
EP2591783A1 (fr) * 2007-04-13 2013-05-15 Millennium Pharmaceuticals, Inc. Combinaison d'une thérapie anticoagulante avec un composé qui agit comme un inhibiteur du facteur Xa
AU2008247435A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet ADP receptor inhibitor
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
ES2740424T3 (es) 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
CN102448951B (zh) 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
SG177434A1 (en) 2009-06-29 2012-02-28 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
CN102625712B (zh) 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法
EP3064595B1 (fr) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Procédés pour des troubles liés à la prolifération cellulaire
CA2784921A1 (fr) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Sels et formes cristallines d'inhibiteur de facteur xa
WO2011075602A1 (fr) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Procédés de préparation d'inhibiteurs du facteur xa et de leurs sels
JP5766204B2 (ja) 2009-12-17 2015-08-19 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の合成方法
EA015918B1 (ru) 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
AR082804A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
CA2821975A1 (fr) 2010-12-17 2012-06-21 Shunqi Yan Derives de n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsufonamide comme modulateur de pyruvate kinase m2 pkm2
ES2569712T3 (es) 2010-12-21 2016-05-12 Agios Pharmaceuticals, Inc. Activadores de PKM2 bicíclicos
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
WO2012151452A1 (fr) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc Activateurs de la pyruvate kinase destinés à une utilisation thérapeutique
PT2704721T (pt) 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013033370A1 (fr) * 2011-08-31 2013-03-07 Portola Pharmaceuticals, Inc. Prévention et traitement de la thrombose chez des patients médicalement malades
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
DK3054936T5 (da) 2013-10-10 2024-03-18 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer
GB201322777D0 (en) * 2013-12-20 2014-02-05 Algipharma As Use of alginate oligomers as blood anticoagulants
AU2015229214B2 (en) 2014-03-14 2019-07-11 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2016201227A1 (fr) 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Procédés d'utilisation d'activateurs de la pyruvate kinase
WO2016205062A1 (fr) * 2015-06-15 2016-12-22 Shifa Biomedical Corporation Thérapies antithrombotiques
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
HRP20211790T1 (hr) 2015-10-15 2022-03-04 Les Laboratoires Servier Kombinirana terapija za liječenje maligniteta
BR112018007671B1 (pt) 2015-10-15 2023-10-17 Les Laboratoires Servier Usos de um inibidor da idh1 e combinações
PE20201164A1 (es) 2017-07-11 2020-10-28 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
CN111148743B (zh) 2017-10-06 2023-12-15 福马治疗有限公司 抑制泛素特异性肽酶30
EA201800084A1 (ru) * 2018-01-19 2019-07-31 Общество С Ограниченной Ответственностью "Фармадиол" НОВЫЕ АМИДИНЫ-ИНГИБИТОРЫ ФАКТОРА Ха
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2019241793A1 (fr) * 2018-06-15 2019-12-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Procédés de détection de l'activation de plaquettes à activation mécanique et utilisations associées
EP4218934A1 (fr) 2018-10-05 2023-08-02 Forma Therapeutics, Inc. Inhibition de la protéase 30 spécifique de l'ubiquitine (usp30)
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
EP4347031A1 (fr) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0813834B2 (ja) * 1990-08-01 1996-02-14 日東紡績株式会社 トリペプチド誘導体及びそれを有効成分とする蛋白分解酵素阻害剤
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
YU8395A (sh) * 1994-02-14 1998-07-10 Kirin Brewery Company Protein sa tpo aktivnošću
JP2002533454A (ja) * 1998-12-23 2002-10-08 イーライ・リリー・アンド・カンパニー 芳香族アミド類
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
ES2254385T3 (es) * 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
GB0021497D0 (en) * 2000-09-01 2000-10-18 Novartis Res Foundation Compounds and their use
US20040077690A1 (en) * 2000-09-29 2004-04-22 Bing-Yan Zhu Quaternary amidino based inhibitors of factor xa
ATE549317T1 (de) * 2005-11-08 2012-03-15 Millennium Pharm Inc Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer

Also Published As

Publication number Publication date
WO2008073670A2 (fr) 2008-06-19
RU2452484C2 (ru) 2012-06-10
AU2007333377B2 (en) 2014-01-16
RU2009126147A (ru) 2011-01-20
ECSP099501A (es) 2010-01-29
CO6220933A2 (es) 2010-11-19
US8404724B2 (en) 2013-03-26
AU2007333377A1 (en) 2008-06-19
CA2913963A1 (fr) 2008-06-19
IL199219A (en) 2013-10-31
HK1134031A1 (en) 2010-04-16
EP2101760B1 (fr) 2013-02-27
IL199219A0 (en) 2010-03-28
CR10914A (es) 2009-08-12
PT2101760E (pt) 2013-05-07
RU2012104816A (ru) 2013-08-20
KR20090107499A (ko) 2009-10-13
WO2008073670A3 (fr) 2008-11-27
KR101472765B1 (ko) 2014-12-15
ES2409090T3 (es) 2013-06-24
CA2671502A1 (fr) 2008-06-19
SG10201504425SA (en) 2015-07-30
EP2101760A2 (fr) 2009-09-23
NI200900145A (es) 2010-11-29
CA2671502C (fr) 2017-01-24
CN105193799A (zh) 2015-12-30
NZ578180A (en) 2012-02-24
US20080153876A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
MA31086B1 (fr) Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa.
CY1111437T1 (el) Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης
EA200802288A1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
CY1116494T1 (el) Θεραπευτικη αγωγη θρομβοεμβολικων διαταραχων με ριβαροξαβανη
EA200802213A1 (ru) Способы лечения заболеваний крови
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
HK1123484A1 (en) Method of using oxidative reductive potential water solution in dental applications
ATE448785T1 (de) Behandlung von entzündlicher darmerkrankung
MA29326B1 (fr) Combinaison de composes organiques
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
BRPI0509468A (pt) 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
ATE339205T1 (de) (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen
ATE476530T1 (de) Neues molekulares target der neurotoxizität
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
ATE451350T1 (de) Arylalkylsulfonamide als therapeutische mittel zur behandlung von knochenleiden
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
EA201070478A1 (ru) Дифенилкарбоновые кислоты и их производные
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten